TOI Share Price Performance
US$3.78
3.58 (1,820.73%)
52.8% undervalued intrinsic discount
US$8.00
Fair Value
Price US$3.78
AnalystHighTarget US$8.00
AnalystConsensusTarget US$7.00
Fair ValueUS$8.00
Share Pricen/a
The Oncology Institute, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
TOI Community Narratives
AN
Fair Value US$8 52.8% undervalued intrinsic discount
Value Based Oncology Expansion And AI Deployment Will Transform Long Term Earnings Power
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$7 46.0% undervalued intrinsic discount
Florida And Nevada Expansions Will Strengthen Community Oncology Care
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Value Based Oncology Expansion And AI Deployment Will Transform Long Term Earnings Power
Catalysts About Oncology Institute The Oncology Institute delivers value based community oncology care supported by an integrated pharmacy and technology enabled platform. What are the underlying business or industry changes driving this perspective?Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$8
52.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
24.09% p.a.
Profit Margin
5.45%
Future PE
24.57x
Price in 2028
US$5.47
Florida And Nevada Expansions Will Strengthen Community Oncology Care
Key Takeaways Rapid expansion of value-based contracts and scaled risk-based care models is driving strong patient growth, margin expansion, and sustainable top-line gains. Market tailwinds, tech investments, and growing pharmacy operations position the company for durable demand, lower costs, and increased profitability.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$7
46.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
19.54% p.a.
Profit Margin
5.39%
Future PE
24.87x
Price in 2028
US$5.48
Trending Discussion
Recently Updated Narratives
AN
Value Based Oncology Expansion And AI Deployment Will Transform Long Term Earnings Power
Fair Value: US$8 52.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Florida And Nevada Expansions Will Strengthen Community Oncology Care
Fair Value: US$7 46.0% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
The Oncology Institute, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.56
- 14.82%
- -11.87%
- -620.8%
About TOI
- Founded
- 2007
- Employees
- 825
- CEO
- WebsiteView website
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
